SARS-CoV-2 Spike Protein Licensed by Oragenics From the NIH Demonstrates Protective Immunity in Mice
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announces that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National Institutes of Health (“NIH”) and licensed by the Company demonstrates protective immunity in immunized mice challenged with mouse-adapted SARS-CoV-2 virus.
UF Health Discovers Possible Risk Factor for COVID-19
A UF research team found vitamin D-deficient patients were four times more likely to be COVID-19 positive than those with a sufficient amount of the crucial vitamin, which people can get from sources like sunlight and animal proteins.
Florida Doctors Push To Make COVID-19 Vaccine Education Accessible in Minority Communities
Data shows that racial and ethnic minorities are more at risk of getting COVID-19, being hospitalized and dying from the virus. There are so many reasons for this disparity: socioeconomic status increased exposure to the virus because of occupation, access to healthcare and education.
Two-Drug Combo Shows Dramatic Results for COVID-19 Patients, UF Health Researchers Find
Combining an anti-inflammatory drug with an antiviral drug reduces recovery time and accelerates improvement for COVID-19 patients, a national study co-authored by UF Health researchers has found.
Two-Drug Combo Shows Dramatic Results for COVID-19 Patients, UF Health Researchers Find
Combining an anti-inflammatory drug with an antiviral drug reduces recovery time and accelerates improvement for COVID-19 patients, a national study co-authored by UF Health researchers has found.
Tapeworm, Vertigo and Pancreatitis Drugs Are Being Trialled As COVID-19 Treatments
Included in this news roundup is UF startup Algernon Pharmaceuticals’s trials with ifenprodil, a drug used to treat vertigo and bird flu. Algernon is testing the drug’s efficacy in preventing lung damage and increasing survivability in patients with COVID-19.
UF Health Researcher Answers Top Questions About the New COVID-19 Vaccines
The leading COVID-19 vaccines aren’t anything like the polio vaccination your grandparents received — or even the flu shot you got this fall. A look under the hood unveils a remarkable advancement in medicine.
New Resident Client at Sid Martin Biotech to Pave Way for Post-COVID Therapy, Regenerative Medicine Research
The inflammation COVID-19 patients suffer during and post-COVID-19 infection (AKA “Post-COVID Syndrome”) will be one of many focuses of a new resident client that recently joined the UF Innovate | Sid Martin Biotech, the world-recognized leader in biotechnology incubation. Neobiosis, which produces regenerative tissues, cells, and extracellular vesicles for research and clinical trials to help the body heal itself—without surgery—will operate a laboratory at the biotech center, located in Alachua.
Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19
UF startup Algernon Pharmaceuticals Inc., formerly known as Breathtec Biomedical, a clinical-stage pharmaceutical development company, announced that the external Data and Safety Monitoring Board (“DSMB”) has completed its latest review of the Phase 2b part of the Company’s Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, and has provided approval for the company to continue on with the Phase 3 part of the study.
Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies for COVID-19 Vaccine Adjuvant
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced entering into a material transfer agreement with Adjuvance Technologies Inc. for use of the adjuvant TQL1055 in the Company’s Terra CoV-2 vaccine against COVID-19.